Korea's AI medical device approvals surge 41% as digital health transforms market

South Korea's medical device market shifted decisively toward artificial intelligence and digital solutions last year, with approvals of AI-powered devices jumping 41.6 percent compared to 2024. The Ministry of Food and Drug Safety released its 2025 Medical Product Approval Report last Thursday, laying out a landscape transformed by technology and shaped by an aging population's needs. The numbers tell a story of a country betting heavily on homegrown innovation: of the 153 AI-based medical devices that won approval or certification, nearly 78 percent were manufactured domestically, suggesting that Korean companies are not just adopting the technology but leading its development.

Digital therapeutics—software-based treatments delivered through apps or devices rather than pills—represent perhaps the most striking shift. A decade ago, these treatments barely existed as a regulatory category. Last year, South Korea approved ten new digital therapeutics, bringing the cumulative total to fourteen, all of them made in Korea. What matters more than the count is the expansion of what these treatments can do. They started with insomnia, a narrow but real clinical need. Now they address pediatric ADHD, eating disorders, and tinnitus. The boundaries between traditional medicine and digital health, once sharp and clear, are dissolving.

The broader pharmaceutical market reflected different pressures. Across all drug categories, 1,397 new pharmaceuticals entered the market in 2025. Twenty-six of these were entirely new drugs—a modest increase of three from the previous year—but the quality mattered. Korea's own companies brought forward the anthrax vaccine Barythrax, a submental fat reduction treatment called Nuviju, and an epilepsy medication named Xcopri. Twenty modified drugs also won approval, most of them treatments for hypertension or diabetes. Diabetes medications dominated the approval landscape overall, with 174 products cleared, reflecting both the disease's prevalence and the intensity of pharmaceutical competition in this space.

Rare disease treatments showed particular momentum. Sixteen biologics for rare conditions received approval last year—eleven distinct active ingredients—marking the highest count in five years. This matters because rare diseases affect small populations and generate little commercial incentive, yet Korea's regulatory system and its companies are moving in this direction anyway. Rare biologics, by their nature, are expensive and complex to develop, yet they're being approved at accelerating rates.

The medical device market, broader and more diverse than pharmaceuticals, told a story shaped by demographics. South Korea's population is aging rapidly, and the device approvals reflected this reality. Hearing aids designed for air conduction received 27 approvals. Multifocal intraocular lenses, which correct vision at multiple distances and appeal to aging eyes, won ten approvals. Dental implant components—superstructures and surgical instruments—accounted for 187 combined approvals. These are not glamorous technologies, but they address the concrete needs of millions of people moving through their sixties, seventies, and beyond.

Aesthetic medicine and the K-beauty industry drove another major category. Tissue repair biomaterials received 122 approvals, up 13 percent from 2024, with more than 95 percent manufactured domestically. These materials support wrinkle improvement, tissue reconstruction, and repair—the infrastructure of the beauty industry that has become one of Korea's most visible global exports. The regulatory system is not just permitting this growth; it is actively enabling it, approving products at a pace that suggests confidence in both the science and the market.

What emerges from these numbers is a portrait of a healthcare market in transition. Korea is not simply importing medical technology from elsewhere; it is manufacturing the future of healthcare at home. The surge in AI devices, the expansion of digital therapeutics, the acceleration of rare disease treatments, and the responsiveness to demographic change all point toward a system that is learning to move quickly while maintaining rigor. The question now is whether this pace can be sustained, and whether the innovations being approved will translate into actual improvements in how people experience illness and aging.